Metoprolol (succinate)

Metoprolol (succinate)

• CAS Number: 98418-47-4
• UNSPSC Description: Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties[1][2][3].
• Target Antigen: Adrenergic Receptor; Apoptosis
• Type: Reference compound
• Related Pathways: Apoptosis;GPCR/G Protein;Neuronal Signaling
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease; Endocrinology; Cancer
• Assay Protocol: https://www.medchemexpress.com/metoprolol-succinate.html
• Solubility: DMSO : 16.67 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL
• Smiles: OC(CNC(C)C)COC1=CC=C(CCOC)C=C1.OC(CNC(C)C)COC2=CC=C(CCOC)C=C2.OC(CCC(O)=O)=O
• Molecular Weight: 652.82
• References & Citations: [1]Ulleryd MA, et al. Metoprolol reduces proinflammatory cytokines and atherosclerosis in ApoE-/- mice. Biomed Res Int. 2014;2014:548783.|[2]Wang D, et al. Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. Gene. 2014 Sep 1;547(2):195-201.|[3]Hajatbeigi B, et al. Cytotoxicity of Metoprolol on Leukemic Cells in Vitro. IJBC 2018; 10(4): 124-129.|[4]Su Q, et al. Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. Exp Clin Cardiol. 2013 Spring;18(2):161-5.Eur J Med Chem. 2024 Dec 5.|J Pharmacol Sci. 2020 Sep;144(1):30-42.|bioRxiv. 2024 Mar 29.|PLoS One. 2024 Aug 14;19(8):e0301875.|Chemosphere. 2019 Jun;225:378-387. |Clin Pharmacol Ther. 2023 Nov 16.|Environ Toxicol. 2023 Dec 2.|Int Immunopharmacol. 2024 Aug 9:140:112894.|J Chromatogr B. 2023 Jun 20, 123804.|J Intern Med. 2024 Jul 29.|J Pharmaceut Biomed. 2020, 113870.|Preprints. 2023 Jun 19.|SSRN. 2024 May 30.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched